When: $1,203 10 EMA reclaim on >3M volume with RSI>55

Then: Add reserve tranche

When: Close >$1,250 on >4M shares with MACD bullish re-cross

Then: Full re-engagement

When: Forward EPS revisions >5% to consensus

Then: Downgrade to Hold

Adjust entry triggers lower, reduce initial deployment from 50% to 25%, and tighten stop-loss to approximately $1,080 (40% risk reduction) rather than the proposed $1,040

• Price below 50 SMA by 2.4% and below 10 EMA by 3.9%, with 50 SMA flattening indicating structural momentum loss
• RSI at 42.95 with bearish divergence from August high; MACD histogram at negative 7.60 and expanding downward
• 38.76x trailing P/E requires 58% EPS growth to $47.23 to justify forward multiple; 70% of consensus yields only $810/share (30% below current)
• Total debt rose 37.6% year-over-year from $39.9B to $54.9B; debt-to-equity at 1.62x well above pharma norms
• Goodwill doubled from $5.77B to $8.85B; $8.94B in new debt issued in single quarter; current ratio dropped from 1.58 to 1.36 in two quarters
• 13th acquisition in one year; CEO publicly stated 'not all these bets will pay off'
• Novo Nordisk's CagriSema under FDA review poses competitive threat to GLP-1 pricing power
• MACD histogram expanding negative, RSI below 50 with bearish divergence, and distribution volume profile argue against initiating position in confirmed weakness
• 89% probability of zero Fed rate cuts in 2026 with rising yields creates elevated discount rate risk for premium-multiple stock

→ vs aggressive: Volume profile showing above-average volume on declines that couldn't hold is distribution, not the 'constructive' accumulation the aggressive analyst described

→ vs aggressive: Forward P/E at 24.49x requires 58% EPS growth; even at 70% delivery, stock would be worth only $810 vs current ~$1,150-$1,175, representing 30% downside

→ vs aggressive: Merida deal framed as '1.6% of enterprise value' ignores this is the 13th acquisition in one year with acknowledged integration risk

→ vs aggressive: Dismissed macro environment as 'not LLY-specific' but 38x earnings multiple is highly sensitive to discount rate changes

→ vs aggressive: Claim that waiting for 200 SMA means 'waiting for a level that probably never gets tested' is pure speculation; momentum deterioration makes testing more probable

HOLD - deploy 33-40% of target allocation initially at current levels, with second tranche on confirmation; position capped at 2% portfolio; optional LLY/NVO hedge recommended

• Aggressive analyst's EPS math flawed: 70% of $47.23 = $33.06, not $42; downside scenario yields ~$810 at 25x (roughly 30% below current price)
• Macro environment constraints on multiple: 89% probability of zero rate cuts in 2026, elevated 10-year yields, oil near $90 creating stagflationary backdrop
• M&A cadence (13 deals in one year) signals organic growth maturing; CEO's CNBC admission that not all will pay off is a yellow flag
• Conservative analyst overreaches on volume analysis; above-average decline volume is corroborating evidence, not standalone distribution signal
• Conservative analyst's $810 downside floor too pessimistic; real downside in moderate disappointment scenario is $900-$1,000 given multiple compression and defensive re-rating potential
• Conservative analyst's $1,080 stop suboptimal; sits above 200 SMA at $1,056, forcing exit before structural support where high-conviction buying occurs
• Structural thesis intact: 54% operating margins, $11B free cash flow, 47.7% revenue growth, ROE over 100%
• Mounjaro CV label expansion and Q3 earnings are catalysts with asymmetric upside not fully priced
• Initial deployment should be 33-40% of target (~$0.7% of portfolio at 2% cap), not aggressive 50% or passive 25%
• Stop-loss tightened to $1,070-$1,090, representing ~7% downside from entry vs aggressive's 9.6%
• Second tranche requires MACD histogram narrowing or positive in addition to price/momentum conditions
• Pair-trade angle: consider hedging long LLY with short/underweight NVO given CagriSema FDA review and GLP-1 duopoly intensification

→ vs aggressive: Valuation math error: 70% of $47.23 = $33.06, not $42; at 25x this gives $810 downside, not the better-looking number presented

→ vs aggressive: Dismissal of macro as 'not LLY-specific' is lazy; at 38x trailing earnings, the discount rate environment and stagflationary pressures are direct constraints on the multiple

→ vs aggressive: Merida deal framing as '1.6% of enterprise value' ignores the cadence signal; 13 deals in one year with CEO admitting some won't work signals organic growth maturing, not confidence

→ vs conservative: Volume-distribution call overreaches; above-average decline volume is consistent with profit-taking, not wholesale institutional distribution; too noisy for standalone signal

→ vs conservative: Downside scenario assumes multiple holds at 24.5x even if growth disappoints; backward assumption—in growth-miss scenario, multiple compresses AND stock re-rates defensively

→ vs conservative: $1,080 stop placement is suboptimal; sits above the 200 SMA at $1,056 where high-conviction structural buying occurs, forcing exit at non-meaningful level

→ vs conservative: Too dismissive of asymmetric upside; Mounjaro CV indication and Q3 earnings are genuine catalysts, and sitting out entirely has real opportunity cost